Literature DB >> 7726520

Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa.

Y Q Xiong1, G Potel, J Caillon, G Stephant, F Jehl, D Bugnon, P Le Conte, D Baron, H Drugeon.   

Abstract

The in vivo efficacy of ciprofloxacin or pefloxacin alone or in combination with fosfomycin was evaluated in experimental aortic valve endocarditis induced in 133 rabbits by a multidrug-susceptible or multidrug-resistant strain of Pseudomonas aeruginosa. Therapy was initiated early (12 h after infection), when bacterial counts in aortic valve vegetations were relatively low, or late (48 h after infection), when vegetations contained a larger inoculum. Antibodies were administered as a continuous 24-h intravenous infusion. Mean steady-state levels of ciprofloxacin (64 mg/kg), pefloxacin (64 mg/kg), and fosfomycin (300 mg/kg) in serum were 2.5, 4.2, and 63.9 mg/liter, respectively. For the multidrug-susceptible strain, all regimens except pefloxacin alone significantly reduced the number of CFU per gram of vegetation versus controls, whether treatment was performed early or late. For the multidrug-resistant strain, none of the regimens showed differences from untreated controls, except ciprofloxacin-fosfomycin, which significantly reduced bacterial counts in vegetations compared with controls when therapy was begun early (4.1 +/- 1.1 log10 CFU/g of vegetation; P < 0.001 versus the control). These data suggest that combination of fosfomycin with ciprofloxacin or pefloxacin is more effective than ciprofloxacin or pefloxacin alone for the therapy of severe infections caused by multidrug-susceptible P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726520      PMCID: PMC162566          DOI: 10.1128/AAC.39.2.496

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Dynamics of ceftazidime-pefloxacin interaction shown by a new killing curve-chequerboard method.

Authors:  H B Drugeon; J Caillon; M E Juvin; J L Pirault
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

2.  Pseudomonas aeruginosa endocarditis in drug addicts.

Authors:  G Archer; F R Fekety; R Supena
Journal:  Am Heart J       Date:  1974-11       Impact factor: 4.749

3.  Determination of fosfomycin in biological fluids by capillary electrophoresis.

Authors:  D Levêque; C Gallion; E Tarral; H Monteil; F Jehl
Journal:  J Chromatogr B Biomed Appl       Date:  1994-05-13

4.  Treatment of patients with pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy.

Authors:  M P Reyes; W J Brown; A M Lerner
Journal:  Medicine (Baltimore)       Date:  1978-01       Impact factor: 1.889

5.  Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria.

Authors:  L J Eron; L Harvey; D L Hixon; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

6.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Authors:  L J Chalkley; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.

Authors:  I Haller
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.

Authors:  N X Chin; K Jules; H C Neu
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

9.  In vitro activity of ciprofloxacin against aerobic gram-negative bacteria.

Authors:  J E Rudin; C W Norden; E M Shinners
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa.

Authors:  M P Reyes; A M Lerner
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  5 in total

1.  Efficacy of ciprofloxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits.

Authors:  Elise Launay; Nicolas Joram; Cédric Jacqueline; Anne Francoise Miegeville; Jocelyne Caillon; Gilles Potel; Jean Christophe Roze; Christèle Gras-Le Guen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-21       Impact factor: 5.191

2.  In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.

Authors:  Olivier Grossi; Jocelyne Caillon; Cedric Arvieux; Cedric Jacqueline; Denis Bugnon; Gilles Potel; Antoine Hamel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

3.  Bactericidal effect of pefloxacin and fosfomycin against Pseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo.

Authors:  D Bugnon; G Potel; Y Q Xiong; J Caillon; D Navas; C Gras; M F Kergueris; P Le Conte; F Jehl; D Baron; H Drugeon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 5.103

Review 4.  Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.

Authors:  Roberta Maria Antonello; Stefano Di Bella; Alberto Enrico Maraolo; Roberto Luzzati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-18       Impact factor: 3.267

5.  Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms.

Authors:  Lei Wang; Mariagrazia Di Luca; Tamta Tkhilaishvili; Andrej Trampuz; Mercedes Gonzalez Moreno
Journal:  Front Microbiol       Date:  2019-11-06       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.